New Year, New Hurdles: What's in Store for Biosimilars in 2023

2023 is gearing up to be a big year for biosimilars, especially in the United States, where up to 10 adalimumab biosimilars referencing Humira, one of the most expensive drugs in the world, will enter the market. In addition to that, we will see the fallout of major government policies, such as the Inflation Reduction Act and the Biosimilars User Fee Amendment, as well as how the market will respond to so many biosimilars entering the market at the same time. How will the first 6 months go? How will payers and pharmacy benefit managers (PBMs) alter their coverage options? Will interchangeability designations make a difference? Will biosimilars be able to get a greater piece of the market pie?

On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.

Show notes

To read more about adalimumab biosimilars, click here.

To read more about ophthalmology biosimilars, click here.

To learn more about the Inflation Reduction Act’s impact on biosimilars, click here.

To read more about the reauthorization of the Biosimilars User Fee Amendment, click here.

To learn more about interchangeability, click here.